Search

Your search keyword '"Asadi-Pooya, Ali A."' showing total 477 results
Start Over Author "Asadi-Pooya, Ali A." Search Limiters Available in Library Collection
477 results on '"Asadi-Pooya, Ali A."'

1. The burden of neurological conditions in north Africa and the Middle East, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019

Author

Avan, Abolfazl, Feigin, Valery L, Bennett, Derrick A., Steinmetz, Jaimie D, Hachinski, Vladimir, Stranges, Saverio, Owolabi, Mayowa O, Aali, Amirali, Abbasi-Kangevari, Mohsen, Abbasi-Kangevari, Zeinab, Abd-Allah, Foad, Abdollahzade, Sina, Abidi, Hassan, Abolhassani, Hassan, Abualhasan, Ahmed, Abu-Gharbieh, Eman, Abu-Rmeileh, Niveen ME, Abu-Zaid, Ahmed, Ahmad, Aqeel, Ahmadi, Sepideh, Ahmed, Luai A, Ajami, Marjan, Al Hamad, Hanadi, Alanezi, Fahad Mashhour, Alanzi, Turki M, Alimohamadi, Yousef, Aljunid, Syed Mohamed, Al-Raddadi, Rajaa M, Amiri, Sohrab, Arabloo, Jalal, Arulappan, Judie, Arumugam, Ashokan, Asadi-Pooya, Ali A, Athar, Mohammad, Athari, Seyyed Shamsadin, Atout, Maha Moh'd Wahbi, Azadnajafabad, Sina, Azangou-Khyavy, Mohammadreza, Azari Jafari, Amirhossein, Azzam, Ahmed Y, Baghcheghi, Nayereh, Bagherieh, Sara, Baltatu, Ovidiu Constantin, Bazmandegan, Gholamreza, Bhojaraja, Vijayalakshmi S, Bijani, Ali, Bitaraf, Saeid, Calina, Daniela, Darwish, Amira Hamed, Djalalinia, Shirin, Doheim, Mohamed Fahmy, Dorostkar, Fariba, Eini, Ebrahim, El Nahas, Nevine, El Sayed, Iman, Elhadi, Muhammed, Elmonem, Mohamed A, Eskandarieh, Sharareh, Faghani, Shahriar, Fallahzadeh, Aida, Farahmand, Mohammad, Ghafourifard, Mansour, Ghamari, Seyyed-Hadi, Gholami, Ali, Ghozy, Sherief, Goleij, Pouya, Hadei, Mostafa, Hafezi-Nejad, Nima, Haj-Mirzaian, Arvin, Halwani, Rabih, Hamidi, Samer, Hasaballah, Ahmed I, Hassan, Amr, Hedna, Khedidja, Hegazy, Mohamed I, Heidari-Soureshjani, Reza, Hosseini, Mohammad-Salar, Hoveidamanesh, Soodabeh, Jahrami, Haitham, Jamshidi, Elham, Javaheri, Tahereh, Jayapal, Sathish Kumar, Kalankesh, Laleh R, Kalhor, Rohollah, Kamiab, Zahra, Keykhaei, Mohammad, Khader, Yousef Saleh, Khan, Maseer, Khan, Moien AB, Khatatbeh, Khayat Kashani, Hamid Reza, Khosravi, Ahmad, Kompani, Farzad, Koohestani, Hamid Reza, Larijani, Bagher, Lasrado, Savita, Magdy Abd El Razek, Mohammed, Malekpour, Mohammad-Reza, Malik, Ahmad Azam, Mansournia, Mohammad Ali, Mardi, Parham, Maroufi, Seyed Farzad, Masoudi, Sahar, Mayeli, Mahsa, Mehrabi Nasab, Entezar, Menezes, Ritesh G, Mirmoeeni, Seyyedmohammadsadeq, Mirza-Aghazadeh-Attari, Mohammad, Mobarakabadi, Maryam, Mohammadi, Esmaeil, Mohammadi, Soheil, Mohan, Syam, Mokdad, Ali H, Momtazmanesh, Sara, Montazeri, Fateme, Moradi Sarabi, Mostafa, Moraga, Paula, Morovatdar, Negar, Motaghinejad, Majid, Naghavi, Mohsen, Natto, Zuhair S, Nejadghaderi, Seyed Aria, Noroozi, Nafise, Okati-Aliabad, Hassan, Pazoki Toroudi, Hamidreza, Perna, Simone, Piradov, Michael A, Pourahmadi, Mohammadreza, Rafiei, Alireza, Rahimi-Movaghar, Vafa, Rahmani, Amir Masoud, Rahmani, Shayan, Rahmanian, Vahid, Rajabpour-Sanati, Ali, Rao, Chythra R, Rashidi, Mohammad-Mahdi, Rawassizadeh, Reza, Razeghian-Jahromi, Iman, Redwan, Elrashdy Moustafa Mohamed, Rezaee, Malihe, Rezaei, Nazila, Rezaei, Negar, Rezaei, Nima, Rezaeian, Mohsen, Rikhtegar, Reza, Saad, Aly M A, Saddik, Basema, Sadeghi, Masoumeh, Sadeghian, Saeid, Saeedi Moghaddam, Sahar, Sahebkar, Amirhossein, Salahi, Saina, Salahi, Sarvenaz, Samy, Abdallah M, Sanadgol, Nima, Sarveazad, Arash, Sathian, Brijesh, Saylan, Mete, Shahbandi, Ataollah, Shahrokhi, Shayan, Shams-Beyranvand, Mehran, Shanawaz, Mohd, Sharifi-Rad, Javad, Sheikhi, Rahim Ali, Shetty, Jeevan K, Shobeiri, Parnian, Shorofi, Seyed Afshin, Siabani, Soraya, Tabatabaei, Seyyed Mohammad, Taheri Abkenar, Yasaman, Taheri Soodejani, Moslem, Temsah, Mohamad-Hani, Vakilian, Alireza, Valadan Tahbaz, Sahel, Valizadeh, Rohollah, Vaziri, Siavash, Vo, Bay, Yahyazadeh Jabbari, Seyed Hossein, Yesiltepe, Metin, Zaki, Nazar, Zare, Iman, Zare Dehnavi, Ali, and Zoladl, Mohammad

Published
2024
Full Text
View/download PDF

2. Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019

Author

Collaborators, GBD 2019 Under-5 Mortality, Paulson, Katherine R, Kamath, Aruna M, Alam, Tahiya, Bienhoff, Kelly, Abady, Gdiom Gebreheat, Abbas, Jaffar, Abbasi-Kangevari, Mohsen, Abbastabar, Hedayat, Abd-Allah, Foad, Abd-Elsalam, Sherief M, Abdoli, Amir, Abedi, Aidin, Abolhassani, Hassan, Abreu, Lucas Guimarães, Abu-Gharbieh, Eman, Abu-Rmeileh, Niveen ME, Abushouk, Abdelrahman I, Adamu, Aishatu L, Adebayo, Oladimeji M, Adegbosin, Adeyinka Emmanuel, Adekanmbi, Victor, Adetokunboh, Olatunji O, Adeyinka, Daniel Adedayo, Adsuar, Jose C, Afshari, Khashayar, Aghaali, Mohammad, Agudelo-Botero, Marcela, Ahinkorah, Bright Opoku, Ahmad, Tauseef, Ahmadi, Keivan, Ahmed, Muktar Beshir, Aji, Budi, Akalu, Yonas, Akinyemi, Oluwaseun Oladapo, Aklilu, Addis, Al-Aly, Ziyad, Alam, Khurshid, Alanezi, Fahad Mashhour, Alanzi, Turki M, Alcalde-Rabanal, Jacqueline Elizabeth, Al-Eyadhy, Ayman, Ali, Tilahun, Alicandro, Gianfranco, Alif, Mohammad, Alipour, Vahid, Alizade, Hesam, Aljunid, Syed Mohamed, Almasi-Hashiani, Amir, Almasri, Nihad A, Al-Mekhlafi, Hesham M, Alonso, Jordi, Al-Raddadi, Rajaa M, Altirkawi, Khalid A, Alumran, Arwa Khalid, Alvis-Guzman, Nelson, Alvis-Zakzuk, Nelson J, Ameyaw, Edward Kwabena, Amini, Saeed, Amini-Rarani, Mostafa, Amit, Arianna Maever L, Amugsi, Dickson A, Ancuceanu, Robert, Anderlini, Deanna, Andrei, Catalina Liliana, Ansari, Fereshteh, Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Antriyandarti, Ernoiz, Anvari, Davood, Anwer, Razique, Aqeel, Muhammad, Arabloo, Jalal, Arab-Zozani, Morteza, Aripov, Timur, Ärnlöv, Johan, Artanti, Kurnia Dwi, Arzani, Afsaneh, Asaad, Malke, Asadi-Aliabadi, Mehran, Asadi-Pooya, Ali A, Jafarabadi, Mohammad Asghari, Athari, Seyyed Shamsadin, Athari, Seyyede Masoume, Atnafu, Desta Debalkie, Atreya, Alok, Atteraya, Madhu Sudhan, Ausloos, Marcel, Awan, Asma Tahir, Quintanilla, Beatriz Paulina Ayala, Ayano, Getinet, Ayanore, Martin Amogre, Aynalem, Yared Asmare, Azari, Samad, Azarian, Ghasem, Azene, Zelalem Nigussie, Darshan, BB, Babaee, Ebrahim, Badiye, Ashish D, and Baig, Atif Amin

Subjects
Infectious Diseases, Perinatal Period - Conditions Originating in Perinatal Period, Prevention, Pediatric, Infection, Good Health and Well Being, COVID-19, Cause of Death, Child, Child Mortality, Child, Preschool, Female, Global Health, Humans, Infant, Infant Mortality, Infant, Newborn, Life Tables, Male, SARS-CoV-2, Sustainable Development, GBD 2019 Under-5 Mortality Collaborators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundSustainable Development Goal 3.2 has targeted elimination of preventable child mortality, reduction of neonatal death to less than 12 per 1000 livebirths, and reduction of death of children younger than 5 years to less than 25 per 1000 livebirths, for each country by 2030. To understand current rates, recent trends, and potential trajectories of child mortality for the next decade, we present the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 findings for all-cause mortality and cause-specific mortality in children younger than 5 years of age, with multiple scenarios for child mortality in 2030 that include the consideration of potential effects of COVID-19, and a novel framework for quantifying optimal child survival.MethodsWe completed all-cause mortality and cause-specific mortality analyses from 204 countries and territories for detailed age groups separately, with aggregated mortality probabilities per 1000 livebirths computed for neonatal mortality rate (NMR) and under-5 mortality rate (U5MR). Scenarios for 2030 represent different potential trajectories, notably including potential effects of the COVID-19 pandemic and the potential impact of improvements preferentially targeting neonatal survival. Optimal child survival metrics were developed by age, sex, and cause of death across all GBD location-years. The first metric is a global optimum and is based on the lowest observed mortality, and the second is a survival potential frontier that is based on stochastic frontier analysis of observed mortality and Healthcare Access and Quality Index.FindingsGlobal U5MR decreased from 71·2 deaths per 1000 livebirths (95% uncertainty interval [UI] 68·3-74·0) in 2000 to 37·1 (33·2-41·7) in 2019 while global NMR correspondingly declined more slowly from 28·0 deaths per 1000 live births (26·8-29·5) in 2000 to 17·9 (16·3-19·8) in 2019. In 2019, 136 (67%) of 204 countries had a U5MR at or below the SDG 3.2 threshold and 133 (65%) had an NMR at or below the SDG 3.2 threshold, and the reference scenario suggests that by 2030, 154 (75%) of all countries could meet the U5MR targets, and 139 (68%) could meet the NMR targets. Deaths of children younger than 5 years totalled 9·65 million (95% UI 9·05-10·30) in 2000 and 5·05 million (4·27-6·02) in 2019, with the neonatal fraction of these deaths increasing from 39% (3·76 million [95% UI 3·53-4·02]) in 2000 to 48% (2·42 million; 2·06-2·86) in 2019. NMR and U5MR were generally higher in males than in females, although there was no statistically significant difference at the global level. Neonatal disorders remained the leading cause of death in children younger than 5 years in 2019, followed by lower respiratory infections, diarrhoeal diseases, congenital birth defects, and malaria. The global optimum analysis suggests NMR could be reduced to as low as 0·80 (95% UI 0·71-0·86) deaths per 1000 livebirths and U5MR to 1·44 (95% UI 1·27-1·58) deaths per 1000 livebirths, and in 2019, there were as many as 1·87 million (95% UI 1·35-2·58; 37% [95% UI 32-43]) of 5·05 million more deaths of children younger than 5 years than the survival potential frontier.InterpretationGlobal child mortality declined by almost half between 2000 and 2019, but progress remains slower in neonates and 65 (32%) of 204 countries, mostly in sub-Saharan Africa and south Asia, are not on track to meet either SDG 3.2 target by 2030. Focused improvements in perinatal and newborn care, continued and expanded delivery of essential interventions such as vaccination and infection prevention, an enhanced focus on equity, continued focus on poverty reduction and education, and investment in strengthening health systems across the development spectrum have the potential to substantially improve U5MR. Given the widespread effects of COVID-19, considerable effort will be required to maintain and accelerate progress.FundingBill & Melinda Gates Foundation.

Published
2021

3. Response to the Letter Concerning the Publication: Neuroimaging in Functional Neurological Disorder: State of the Field and Research Agenda. Perez DL et al. Neuroimage Clin. 2021;30:102623

Author

Perez, David L., Nicholson, Timothy R., Asadi-Pooya, Ali A., Butler, Matthew, Carson, Alan J., David, Anthony S., Deeley, Quinton, Diez, Ibai, Edwards, Mark J., Espay, Alberto J., Gelauff, Jeannette M., Jungilligens, Johannes, Hallett, Mark, Kanaan, Richard A.A., Tijssen, Marina A.J., Kozlowska, Kasia, LaFrance, W. Curt, Jr, Marapin, Ramesh S., Maurer, Carine W., Reinders, Antje A.T.S., Sojka, Petr, Staab, Jeffrey P., Stone, Jon, Szaflarski, Jerzy P., and Aybek, Selma

Published
2024
Full Text
View/download PDF

5. Five insights from the Global Burden of Disease Study 2019

Author

Collaborators, GBD 2019 Viewpoint, Murray, Christopher JL, Abbafati, Cristiana, Abbas, Kaja M, Abbasi, Mohammad, Abbasi-Kangevari, Mohsen, Abd-Allah, Foad, Abdollahi, Mohammad, Abedi, Parisa, Abedi, Aidin, Abolhassani, Hassan, Aboyans, Victor, Abreu, Lucas Guimarães, Abrigo, Michael RM, Abu-Gharbieh, Eman, Abu Haimed, Abdulaziz Khalid, Abushouk, Abdelrahman I, Acebedo, Alyssa, Ackerman, Ilana N, Adabi, Maryam, Adamu, Abdu A, Adebayo, Oladimeji M, Adelson, Jaimie D, Adetokunboh, Olatunji O, Afarideh, Mohsen, Afshin, Ashkan, Agarwal, Gina, Agrawal, Anurag, Ahmad, Tauseef, Ahmadi, Keivan, Ahmadi, Mehdi, Ahmed, Muktar Beshir, Aji, Budi, Akinyemiju, Tomi, Akombi, Blessing, Alahdab, Fares, Alam, Khurshid, Alanezi, Fahad Mashhour, Alanzi, Turki M, Albertson, Samuel B, Alemu, Biresaw Wassihun, Alemu, Yihun Mulugeta, Alhabib, Khalid F, Ali, Muhammad, Ali, Saqib, Alicandro, Gianfranco, Alipour, Vahid, Alizade, Hesam, Aljunid, Syed Mohamed, Alla, François, Allebeck, Peter, Almadi, Majid Abdulrahman Hamad, Almasi-Hashiani, Amir, Al-Mekhlafi, Hesham M, Almulhim, Abdulaziz M, Alonso, Jordi, Al-Raddadi, Rajaa M, Altirkawi, Khalid A, Alvis-Guzman, Nelson, Amare, Bekalu, Amare, Azmeraw T, Amini, Saeed, Amit, Arianna Maever L, Amugsi, Dickson A, Anbesu, Etsay Woldu, Ancuceanu, Robert, Anderlini, Deanna, Anderson, Jason A, Andrei, Tudorel, Andrei, Catalina Liliana, Anjomshoa, Mina, Ansari, Fereshteh, Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Antony, Catherine M, Anvari, Davood, Appiah, Seth Christopher Yaw, Arabloo, Jalal, Arab-Zozani, Morteza, Aravkin, Aleksandr Y, Arba, Aseb Arba Kinfe, Aripov, Timur, Ärnlöv, Johan, Arowosegbe, Oluwaseyi Olalekan, Asaad, Malke, Asadi-Aliabadi, Mehran, Asadi-Pooya, Ali A, Ashbaugh, Charlie, Assmus, Michael, Atout, Maha Moh'd Wahbi, Ausloos, Marcel, Ausloos, Floriane, Quintanilla, Beatriz Paulina Ayala, Ayano, Getinet, Ayanore, Martin Amogre, Azari, Samad, Azene, Zelalem Nigussie, Darshan, BB, Babaee, Ebrahim, and Badawi, Alaa

Subjects
Prevention, 2.4 Surveillance and distribution, Aetiology, Good Health and Well Being, Birth Rate, Delivery of Health Care, Female, Global Burden of Disease, Global Health, Humans, Male, Noncommunicable Diseases, Outcome Assessment, Health Care, Risk Factors, Socioeconomic Factors, Wounds and Injuries, GBD 2019 Viewpoint Collaborators, Medical and Health Sciences, General & Internal Medicine
Abstract

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a rules-based synthesis of the available evidence on levels and trends in health outcomes, a diverse set of risk factors, and health system responses. GBD 2019 covered 204 countries and territories, as well as first administrative level disaggregations for 22 countries, from 1990 to 2019. Because GBD is highly standardised and comprehensive, spanning both fatal and non-fatal outcomes, and uses a mutually exclusive and collectively exhaustive list of hierarchical disease and injury causes, the study provides a powerful basis for detailed and broad insights on global health trends and emerging challenges. GBD 2019 incorporates data from 281 586 sources and provides more than 3·5 billion estimates of health outcome and health system measures of interest for global, national, and subnational policy dialogue. All GBD estimates are publicly available and adhere to the Guidelines on Accurate and Transparent Health Estimate Reporting. From this vast amount of information, five key insights that are important for health, social, and economic development strategies have been distilled. These insights are subject to the many limitations outlined in each of the component GBD capstone papers.

Published
2020

7. Physicians’ beliefs about brain surgery for drug-resistant epilepsy: A global survey

Author

Asadi-Pooya, Ali A., Brigo, Francesco, Trinka, Eugen, Lattanzi, Simona, Karakis, Ioannis, Kishk, Nirmeen Adel, Valente, Kette D., Jusupova, Asel, Turuspekova, Saule T., Daza-Restrepo, Anilu, Contreras, Guilca, Kutlubaev, Mansur A., Guekht, Alla, Rahimi-Jaberi, Abbas, Aljandeel, Ghaieb, Calle-Lopez, Yamile, Alsaadi, Taoufik, Ashkanani, Abdulaziz, Ranganathan, Lakshmi Narasimhan, Al-Asmi, Abdullah, Khachatryan, Samson G., Gigineishvili, David, Mesraoua, Boulenouar, and Mwendaweli, Naluca

Published
2022
Full Text
View/download PDF

10. Individualised prediction of drug resistance and seizure recurrence after medication withdrawal in people with juvenile myoclonic epilepsy: A systematic review and individual participant data meta-analysis

Author

Stevelink, Remi, Al-Toma, Dania, Jansen, Floor E., Lamberink, Herm J., Asadi-Pooya, Ali A., Farazdaghi, Mohsen, Cação, Gonçalo, Jayalakshmi, Sita, Patil, Anuja, Özkara, Çiğdem, Aydın, Şenay, Gesche, Joanna, Beier, Christoph P., Stephen, Linda J., Brodie, Martin J., Unnithan, Gopeekrishnan, Radhakrishnan, Ashalatha, Höfler, Julia, Trinka, Eugen, Krause, Roland, Irelli, Emanuele Cerulli, Di Bonaventura, Carlo, Szaflarski, Jerzy P., Hernández-Vanegas, Laura E., Moya-Alfaro, Monica L., Zhang, Yingying, Zhou, Dong, Pietrafusa, Nicola, Specchio, Nicola, Japaridze, Giorgi, Beniczky, Sándor, Janmohamed, Mubeen, Kwan, Patrick, Syvertsen, Marte, Selmer, Kaja K., Vorderwülbecke, Bernd J., Holtkamp, Martin, Viswanathan, Lakshminarayanapuram G., Sinha, Sanjib, Baykan, Betül, Altindag, Ebru, von Podewils, Felix, Schulz, Juliane, Seneviratne, Udaya, Viloria-Alebesque, Alejandro, Karakis, Ioannis, D'Souza, Wendyl J., Sander, Josemir W., Koeleman, Bobby P.C., Otte, Willem M., and Braun, Kees P.J.

Published
2022
Full Text
View/download PDF

12. Generalized spike–waves in idiopathic generalized epilepsies: Does their frequency matter?

Author

Asadi‐Pooya, Ali A. and Farazdaghi, Mohsen

Abstract

Objectives: We hypothesized that the frequency (in Hertz) of generalized spike–waves (GSWs) in patients with idiopathic generalized epilepsy (IGE) has associations with the syndromic diagnosis as well as with the prognosis of patients (their response to medical treatment). Methods: This was a retrospective study of a prospectively developed database. All patients with a diagnosis of IGE were studied at the epilepsy center at Shiraz University of Medical Sciences, Shiraz, Iran, from 2008 until 2022. Patients were classified into four IGE syndromes: childhood absence epilepsy; juvenile absence epilepsy; juvenile myoclonic epilepsy; and generalized tonic–clonic seizures alone. Results: Five hundred and eighty‐three patients were studied. GSWs were commonly observed in all four syndromes of IGE. Frequency of GSW (in Hertz) did not have a significant association with the syndromic diagnosis of the patients (p =.179). The presence of GSW did not have a significant association with the seizure outcome (becoming seizure free or not) of the patients (p =.416). Frequency of GSW did not have a significant association with the seizure outcome of the patients either (p =.574). Conclusion: GSWs are the hallmark electroencephalographic footprints of idiopathic generalized epilepsies; however, neither their presence nor their frequency has practical associations with the syndromic diagnosis of IGEs or their outcome (response to treatment). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. AR2, a novel automatic muscle artifact reduction software method for ictal EEG interpretation: Validation and comparison of performance with commercially available software.

Author

Weiss, Shennan Aibel, Asadi-Pooya, Ali A, Vangala, Sitaram, Moy, Stephanie, Wyeth, Dale H, Orosz, Iren, Gibbs, Michael, Schrader, Lara, Lerner, Jason, Cheng, Christopher K, Chang, Edward, Rajaraman, Rajsekar, Keselman, Inna, Churchman, Perdro, Bower-Baca, Christine, Numis, Adam L, Ho, Michael G, Rao, Lekha, Bhat, Annapoorna, Suski, Joanna, Asadollahi, Marjan, Ambrose, Timothy, Fernandez, Andres, Nei, Maromi, Skidmore, Christopher, Mintzer, Scott, Eliashiv, Dawn S, Mathern, Gary W, Nuwer, Marc R, Sperling, Michael, Engel, Jerome, and Stern, John M

Subjects
electroencephalogram, independent component analysis, muscle artifact, scalp EEG, seizure, Neurodegenerative, Epilepsy, Neurosciences, Brain Disorders, Clinical Research, Neurological, Biochemistry and Cell Biology, Clinical Sciences, Oncology and Carcinogenesis
Abstract

Objective: To develop a novel software method (AR2) for reducing muscle contamination of ictal scalp electroencephalogram (EEG), and validate this method on the basis of its performance in comparison to a commercially available software method (AR1) to accurately depict seizure-onset location. Methods: A blinded investigation used 23 EEG recordings of seizures from 8 patients. Each recording was uninterpretable with digital filtering because of muscle artifact and processed using AR1 and AR2 and reviewed by 26 EEG specialists. EEG readers assessed seizure-onset time, lateralization, and region, and specified confidence for each determination. The two methods were validated on the basis of the number of readers able to render assignments, confidence, the intra-class correlation (ICC), and agreement with other clinical findings. Results: Among the 23 seizures, two-thirds of the readers were able to delineate seizure-onset time in 10 of 23 using AR1, and 15 of 23 using AR2 (p

Published
2017

20. How Does COVID-19 Vaccination Affect Long-COVID Symptoms?

Author

Asadi-Pooya, Ali Akbar, Nemati, Meshkat, Shahisavandi, Mina, Nemati, Hamid, Karimi, Afrooz, Jafari, Anahita, Nasiri, Sara, Mohammadi, Seyyed Saeed, Rahimian, Zahra, Bayat, Hossein, Akbari, Ali, Emami, Amir, Eilami, Owrang, Asadi-Pooya, Ali Akbar, Nemati, Meshkat, Shahisavandi, Mina, Nemati, Hamid, Karimi, Afrooz, Jafari, Anahita, Nasiri, Sara, Mohammadi, Seyyed Saeed, Rahimian, Zahra, Bayat, Hossein, Akbari, Ali, Emami, Amir, and Eilami, Owrang

Abstract

OBJECTIVE: The current study aimed to identify the association between COVID-19 vaccination and prolonged post-COVID symptoms (long-COVID) in adults who reported suffering from this condition. METHODS: This was a retrospective follow-up study of adults with long-COVID syndrome. The data were collected during a phone call to the participants in January-February 2022. We inquired about their current health status and also their vaccination status if they agreed to participate. RESULTS: In total, 1236 people were studied; 543 individuals reported suffering from long long- COVID (43.9%). Chi square test showed that 15 out of 51 people (29.4%) with no vaccination and 528 out of 1185 participants (44.6%) who received at least one dose of any vaccine had long long- COVID symptoms (p = 0.032). CONCLUSIONS: In people who have already contracted COVID-19 and now suffer from long-COVID, receiving a COVID vaccination has a significant association with prolonged symptoms of long-COVID for more than one year after the initial infection. However, vaccines reduce the risk of severe COVID-19 (including reinfections) and its catastrophic consequences (e.g., death). Therefore, it is strongly recommended that all people, even those with a history of COVID-19, receive vaccines to protect themselves against this fatal viral infection.

Published
2024

25. How does COVID-19 vaccination affect long-COVID symptoms?

Author

Asadi-Pooya, Ali A., primary, Nemati, Meshkat, additional, Shahisavandi, Mina, additional, Nemati, Hamid, additional, Karimi, Afrooz, additional, Jafari, Anahita, additional, Nasiri, Sara, additional, Mohammadi, Seyyed Saeed, additional, Rahimian, Zahra, additional, Bayat, Hossein, additional, Akbari, Ali, additional, Emami, Amir, additional, and Eilami, Owrang, additional

Published
2024
Full Text
View/download PDF

33. Interactions between antiseizure medications and foods and drinks: A systematic review.

Author

Asadi‐Pooya, Ali A., Johannessen Landmark, Cecilie, Mirzaei Damabi, Nafiseh, and Fazelian, Khatereh

Abstract

Antiseizure medications (ASMs) constitute the principal of treatment for patients with epilepsy, where long‐term treatment is usually necessary. The purpose of this systematic review is to provide practical and useful information regarding various aspects of the interactions between ASMs and foods and drinks. MEDLINE and ScienceDirect, from the inception to July 15, 2023, were searched for related publications. In both electronic databases, the following search strategy was applied, and the following keywords were used (in title/abstract): "food OR drink" AND "antiepileptic OR antiseizure." The primary search yielded 738 studies. After implementing our inclusion and exclusion criteria, we could identify 19 studies on the issue of interest for our endeavor. Four studies were identified in the recheck process and not by the primary search. All studies provided low level of evidence. Interactions between foods and ASMs are a common phenomenon. Many factors may play a role for such an interaction to come to play; these include drug properties, administration route, and administration schedule, among others. Drugs‐foods (‐drinks) interactions may change the drug exposure or plasma levels of drugs (e.g., grapefruit juice increases carbamazepine concentrations and the bioavailability of cannabidiol is increased 4–5 folds with concomitant intake of fat‐rich food); this may require dosage adjustments. Interactions between ASMs and foods and drinks may be important. This should be taken seriously into consideration when consulting patients and their caregivers about ASMs. Future well‐designed investigations should explore the specific interactions between foods (and drinks) and ASMs to clarify whether they are clinically important. Plain Language Summary: Interactions between antiseizure medications and foods and drinks may be important. This should be taken into consideration in patients with epilepsy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Nano‐delivery systems as a promising therapeutic potential for epilepsy: Current status and future perspectives

Author

Movahedpour, Ahmad, primary, Taghvaeefar, Rasul, additional, Asadi‐Pooya, Ali‐Akbar, additional, Karami, Yousof, additional, Tavasolian, Ronia, additional, Khatami, Seyyed Hossein, additional, Soltani Fard, Elahe, additional, Taghvimi, Sina, additional, Karami, Neda, additional, Rahimi Jaberi, Khojaste, additional, Taheri‐Anganeh, Mortaza, additional, and Ghasemi, Hassan, additional

Published
2023
Full Text
View/download PDF

46. Use of Integrative, Complementary, and Alternative Medicine in Children with Epilepsy: A Global Scoping Review

Author

Zhu, Zahra, primary, Dluzynski, Daniela, additional, Hammad, Nouran, additional, Pugalenthi, Deepika, additional, Walser, Sarah A., additional, Mittal, Rea, additional, Samanta, Debopam, additional, Brown, Melanie L., additional, Asadi-Pooya, Ali A., additional, Kakooza-Mwesige, Angelina, additional, Spalice, Alberto, additional, Capponi, Martina, additional, Lekoubou, Alain, additional, Kumar, Ashutosh, additional, Paudel, Sita, additional, Carney, Paul R., additional, Mainali, Gayatra, additional, and Naik, Sunil, additional

Published
2023
Full Text
View/download PDF

48. Genetics of Functional Seizures; A Scoping Systematic Review

Author

Asadi-Pooya, Ali A., Hallett, Mark, Mirzaei Damabi, Nafiseh, Fazelian Dehkordi, Khatereh, Asadi-Pooya, Ali A., Hallett, Mark, Mirzaei Damabi, Nafiseh, and Fazelian Dehkordi, Khatereh

Abstract

Background: Evidence on the genetics of functional seizures is scarce, and the purpose of the current scoping systematic review is to examine the existing evidence and propose how to advance the field. Methods: Web of science and MEDLINE were searched, from their initiation until May 2023. The following key words were used: functional neurological disorder(s), psychogenic neurological disorder(s), functional movement disorder(s), psychogenic movement disorder(s), functional seizures(s), psychogenic seizure(s), nonepileptic seizure(s), dissociative seizure(s), or psychogenic nonepileptic seizure(s), AND, gene, genetic(s), polymorphism, genome, epigenetics, copy number variant, copy number variation(s), whole exome sequencing, or next-generation sequencing. Results: We identified three original studies. In one study, the authors observed that six (5.9%) patients with functional seizures carried pathogenic/likely pathogenic variants. In another study, the authors observed that, in functional seizures, there was a significant correlation with genes that are over-represented in adrenergic, serotonergic, oxytocin, opioid, and GABA receptor signaling pathways. In the third study, the authors observed that patients with functional seizures, as well as patients with depression, had significantly different genotypes in FKBP5 single nucleotide polymorphisms compared with controls. Conclusion: Future genetic investigations of patients with functional seizures would increase our understanding of the pathophysiological and neurobiological problems underlying this common neuropsychological stress-associated condition.

Published
2023

49. Antiseizure Effects of Peganum harmala L. and Lavandula angustifolia

Author

Rahimian, Zahra, Sadrian, SeyedHassan, Shahisavandi, Mina, Aligholi, Hadi, Zarshenas, Mohammad M., Abyar, Alireza, Zeraatpisheh, Zahra, Asadi-Pooya, Ali A., Rahimian, Zahra, Sadrian, SeyedHassan, Shahisavandi, Mina, Aligholi, Hadi, Zarshenas, Mohammad M., Abyar, Alireza, Zeraatpisheh, Zahra, and Asadi-Pooya, Ali A.

Abstract

Peganum harmala L. and Lavandula angustifolia are two traditional herbs with probable antiseizure effects. This study evaluated the effects of these two herbal extracts on pentylenetetrazol- (PTZ-) induced seizures in mice. We prepared hydroalcoholic extracts using P. harmala seeds and the aerial parts of L. angustifolia and then randomly divided 190 mice into 19 groups. Normal saline (10 mg/kg), diazepam (2 mg/kg), P. harmala (2.5, 5, 10, 15, 30, 45, and 60 mg/kg), and L. angustifolia (200, 400, 600, and 800 mg/kg) were intraperitoneally (IP) administrated 30 min before an IP administration of PTZ (90 mg/kg). Animals were observed for behavioral changes for one hour. In addition, the effects of flumazenil and naloxone on the antiseizure activity of P. harmala and L. angustifolia were assessed. P. harmala showed antiseizure activity at the dose of 10 mg/kg; it prolonged the seizure latency and decreased the seizure duration. The mortality protection rate was 90% for this herbal extract. L. angustifolia (600 mg/kg) prolonged the seizure latency and decreased both seizure duration and mortality. Neither flumazenil nor naloxone significantly reversed the antiseizure activities of P. harmala and L. angustifolia. In mice, the hydroalcoholic extracts of P. harmala and L. angustifolia showed antiseizure activity against PTZ-induced seizures. We could not delineate the exact antiseizure mechanisms of these extracts in the current study.

Published
2023

50. Use of Integrative, Complementary, and Alternative Medicine in Children With Epilepsy: A Global Scoping Review

Author

Zhu, Zahra, Dluzynski, Daniela, Hammad, Nouran, Pugalenthi, Deepika, Walser, Sarah A., Mittal, Rea, Samanta, Debopam, Brown, Melanie L., Asadi-Pooya, Ali A., Kakooza-Mwesige, Angelina, Spalice, Alberto, Capponi, Martina, Lekoubou, Alain, Kumar, Ashutosh, Paudel, Sita, Carney, Paul R., Mainali, Gayatra, Naik, Sunil, Zhu, Zahra, Dluzynski, Daniela, Hammad, Nouran, Pugalenthi, Deepika, Walser, Sarah A., Mittal, Rea, Samanta, Debopam, Brown, Melanie L., Asadi-Pooya, Ali A., Kakooza-Mwesige, Angelina, Spalice, Alberto, Capponi, Martina, Lekoubou, Alain, Kumar, Ashutosh, Paudel, Sita, Carney, Paul R., Mainali, Gayatra, and Naik, Sunil

Abstract

(1) Background: Epilepsy is one of the most common chronic neurological disorders in childhood. Complementary and alternative medicine (CAM) use is highly prevalent in patients with epilepsy. Despite CAM’s widespread and increasing popularity, its prevalence, forms, perceived benefits, and potential risks in pediatric epilepsy are rarely explored. (2) Methods: We performed a scoping review of the available literature on the use of CAM in pediatric epilepsy. (3) Results: Overall, global cross-sectional studies showed a variable degree of CAM usage among children with epilepsy, ranging from 13 to 44% in prevalence. Popular types of CAMs reported were supplements, cannabis products, aromatherapy, herbal remedies, dietary therapy, massage therapy, and prayer. Families often report that CAM is effective, although there are limited objective measures of this. Potential risks lie in the use of CAM, such as herbal remedies, and/or unregulated, contaminated, or unpurified products. Studies also underscored inadequate patient–physician discussions regarding CAM. (4) Conclusions: A better understanding of this topic would aid clinicians in guiding patients/families on the use of CAM. Further studies on the efficacy of the different types of CAM used, as well as potential side effects and drug interactions are needed.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results